Datopotamab Deruxtecan vs Sacituzumab Tirumotecan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: TROP2 · full Non-Small Cell Lung Cancer pipeline
Datopotamab Deruxtecan
Marketed by Daiichi Sankyo and partners
NCT04656652 · Phase 3 · active, not recruiting
This open-label, randomized Phase III trial (TROPION-Lung01) assigned 604 patients with previously treated advanced or metastatic non-small cell lung cancer to datopotamab deruxtecan or docetaxel. It had two primary endpoints, progression-free survival and overall survival. Progression-free survival improved significantly (hazard ratio 0.75, P=.004), but overall survival showed only a numerical benefit that did not reach statistical significance (hazard ratio 0.94, P=.530). One primary was met and one was missed, so the result is mixed. Source: the peer-reviewed paper (Ahn et al., J Clin Oncol 2025).
Next expected readout: January 2027 · NCT06417814 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) As Assessed by Blinded Independent Central Review (BICR) Per RECIST v1.1 Following DS-1062a Versus Docetaxel (From randomization until disease progression or death (whichever occurs first), up to approximately 27 months); Overall Survival (OS) Following DS-1062a Versus Docetaxel (From randomization until date of death due to any cause, up to to approximately 38 months): Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025). (mixed)
Result source: NCT04656652
Sacituzumab Tirumotecan
Marketed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and partners
NCT05870319 · Phase 3 · active, not recruiting
This is a randomized, adequately sized (n=376) trial with an active comparator (standard chemotherapy) and a hard clinical endpoint (progression-free survival), and the result was strongly positive favoring the drug. However, the study was conducted open-label with no blinding, which limits confidence in a design that would otherwise support a top-tier grade despite the clear and statistically robust result.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: November 2026 · NCT06448312 (registry estimate)
Reported efficacy
Progression-free survival (PFS) (From baseline until disease progression, death, or other protocol defined reason,up to approximately 36 months): OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001 (met)
Result source: NCT05870319
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Datopotamab Deruxtecan | Sacituzumab Tirumotecan |
|---|---|---|
| PFS, median | 4.4 vs 3.7vs DocetaxelNCT046566521 other result
| —Trial running · NCT05870319 |
| OS, median | 12.9 vs 11.8vs DocetaxelNCT04656652 | —Trial running · NCT05870319 |
| ORR | 35.8%bNCT04484142 | —Trial running · NCT05870319 |
| Duration of response, median | —Trial running · NCT04656652 | —Trial running · NCT05870319 |
PFS, median
- Datopotamab Deruxtecan
- 4.4 vs 3.7vs DocetaxelNCT04656652
1 other result
- 4.4 vs 3 NCT04656652
- Sacituzumab Tirumotecan
- —Trial running · NCT05870319
OS, median
- Datopotamab Deruxtecan
- 12.9 vs 11.8vs DocetaxelNCT04656652
- Sacituzumab Tirumotecan
- —Trial running · NCT05870319
ORR
- Datopotamab Deruxtecan
- 35.8%bNCT04484142
- Sacituzumab Tirumotecan
- —Trial running · NCT05870319
Duration of response, median
- Datopotamab Deruxtecan
- —Trial running · NCT04656652
- Sacituzumab Tirumotecan
- —Trial running · NCT05870319
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Datopotamab Deruxtecan: 4 of 4 rows · Sacituzumab Tirumotecan: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Datopotamab Deruxtecan |
|---|---|
| Dropout rate | 77.3%6.0 mg/kga NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more result85.4%6.0 mg/kg Q3W NCT04484142 · Phase 2 |
| Discontinued due to AEs | —6.0 mg/kga NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more result9.5%6.0 mg/kg Q3W NCT04484142 · Phase 2 |
| Serious AEs | 31%6.0 mg/kga NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more result24.8%6.0 mg/kg Q3W NCT04484142 · Phase 2 |
| Most frequent reported AEs | 6.0 mg/kga stomatitis 49.8% nausea 37.7% alopecia 32% NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more result |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Datopotamab Deruxtecan
show 1 more result
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: TROP2 · full HR+/HER2- Metastatic Breast Cancer pipeline
Datopotamab Deruxtecan
Marketed by Daiichi Sankyo and partners
NCT05104866 · Phase 3 · active, not recruiting
Patients were randomized (365 vs 367) against active chemotherapy, but the study was open-label with no masking. The two co-primary endpoints disagreed: progression-free survival was significantly better (hazard ratio 0.63, p<0.0001) while overall survival showed no difference (hazard ratio 1.01, p=0.9445).
Next expected readout: May 2027 · NCT04644068 (registry estimate)
Reported efficacy
Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months); Overall Survival (From date of randomization until death due to any cause. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.): Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5) (mixed)
Result source: NCT05104866
Sacituzumab Tirumotecan
Marketed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06081959 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Datopotamab Deruxtecan | Sacituzumab Tirumotecan |
|---|---|---|
| PFS, median | 6.9 vs 4.9vs Investigator's Choice of Chemotherapy (ICC)NCT051048661 other result
| —Trial running · NCT06312176 |
| OS, median | 18.6 vs 18.3vs Investigator's Choice of Chemotherapy (ICC)NCT05104866 | —Trial running · NCT06312176 |
| ORR | —Trial running · NCT05104866 | —Trial running · NCT06312176 |
| Clinical benefit rate | —Trial running · NCT05104866 | —Trial running · NCT06312176 |
PFS, median
- Datopotamab Deruxtecan
- 6.9 vs 4.9vs Investigator's Choice of Chemotherapy (ICC)NCT05104866
1 other result
- 6.9 vs 4.5 NCT05104866
- Sacituzumab Tirumotecan
- —Trial running · NCT06312176
OS, median
- Datopotamab Deruxtecan
- 18.6 vs 18.3vs Investigator's Choice of Chemotherapy (ICC)NCT05104866
- Sacituzumab Tirumotecan
- —Trial running · NCT06312176
ORR
- Datopotamab Deruxtecan
- —Trial running · NCT05104866
- Sacituzumab Tirumotecan
- —Trial running · NCT06312176
Clinical benefit rate
- Datopotamab Deruxtecan
- —Trial running · NCT05104866
- Sacituzumab Tirumotecan
- —Trial running · NCT06312176
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Sacituzumab Tirumotecan: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Datopotamab Deruxtecan: 2 of 4 rows · Sacituzumab Tirumotecan: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Datopotamab Deruxtecan |
|---|---|
| Dropout rate | n/a: no completion milestone NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Discontinued due to AEs | — NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Serious AEs | 17.2% NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Most frequent reported AEs | nausea 56.7% stomatitis 52.2% alopecia 37.8% NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Datopotamab Deruxtecan
show 1 more result
show 1 more result
Breast Cancer
Shared mechanism: TROP2 · full Breast Cancer pipeline
Datopotamab Deruxtecan
Marketed by Daiichi Sankyo and partners
NCT05104866 · Phase 3 · active, not recruiting
Patients were randomized (365 vs 367) against active chemotherapy, but the study was open-label with no masking. The two co-primary endpoints disagreed: progression-free survival was significantly better (hazard ratio 0.63, p<0.0001) while overall survival showed no difference (hazard ratio 1.01, p=0.9445).
Next expected readout: May 2027 · NCT04644068 (registry estimate)
Reported efficacy
Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months); Overall Survival (From date of randomization until death due to any cause. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.): Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5) (mixed)
Result source: NCT05104866
Sacituzumab Tirumotecan
Marketed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and partners
NCT05347134 · Phase 3 · active, not recruiting
This was a randomized, adequately sized (n=254) phase 3 trial with an active chemotherapy comparator and a hard clinical endpoint (progression-free survival, reviewed independently), and it clearly succeeded, showing a large PFS benefit for sac-TMT over chemotherapy. However, the trial was open-label with no blinding of patients or investigators, which limits confidence in any endpoints subject to subjective influence, so despite the strong result this design element keeps the grade at moderate rather than the highest tier.
Next expected readout: December 2026 · NCT06081959 (registry estimate)
Reported efficacy
Progression-free survival (PFS) (up to 24 months): OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001 (met)
Result source: NCT05347134
Results for Breast Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Datopotamab Deruxtecan
show 1 more result
show 1 more result
Available safety results
Datopotamab Deruxtecan
| Dropout rate | n/a: no completion milestone NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
|---|---|
| Discontinued due to AEs | — NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Serious AEs | 17.2% NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Most frequent reported AEs | nausea 56.7% stomatitis 52.2% alopecia 37.8% NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Datopotamab Deruxtecan's landscape · Sacituzumab Tirumotecan's landscape